Core Insights - Arla Foods Ingredients has launched a new instant soluble whey protein ingredient, Lacprodan® BLG-100 Acidic, specifically designed for medical nutrition products to address common issues such as poor taste and adherence among patients [1][4] Industry Overview - Malnutrition is prevalent among hospitalized patients, with up to 50% affected, leading to extended hospital stays, decreased quality of life, increased mortality rates, and higher medical costs [3] - Many patients struggle to meet their protein intake through oral nutritional supplements due to poor taste and texture, with surveys indicating that about half of patients do not adhere to their clinical nutrition plans [3] Product Features - Lacprodan® BLG-100 Acidic provides 10 grams of high-quality whey protein per 100 milliliters, featuring excellent solubility and a pleasant taste without bitterness or astringency [4] - The product dissolves completely in both cold and hot beverages within 30 seconds, making it suitable for various applications, including full and non-full nutritional medical foods [4] - It contains all nine essential amino acids, particularly leucine, which is known to stimulate muscle protein synthesis, making it ideal for patients at risk of muscle loss [4][5] Application Potential - Arla Foods Ingredients has developed two innovative applications for Lacprodan® BLG-100 Acidic: a juice-based clinical nutrition drink and a milk-based ready-to-drink beverage, both of which can be easily mixed into various foods and drinks [5] - These products aim to provide patients with more flexible, convenient, and enjoyable options for increasing protein intake throughout the day [5]

Core Viewpoint - Zhejiang Zuoli Pharmaceutical Co., Ltd. announced the acquisition of core assets related to multi-trace element injection solutions from Tibet Future Biopharmaceutical Co., Ltd. for 356 million yuan (including tax) [1] Group 1: Acquisition Details - The asset group includes already marketed products "Multi-trace Element Injection (I)" and "Multi-trace Element Injection (II)", as well as the in-development "Multi-trace Element Injection (III)", along with relevant R&D and production technical data, marketing licenses, trademarks, patents, contractual rights and obligations, and employee labor relations [2] - The "Multi-trace Element Injection (I)" is the first exclusive pediatric-specific parenteral nutrition preparation in China, with very few companies holding the relevant approvals for such products, creating a natural high market barrier [2] Group 2: Company Performance - Zuoli Pharmaceutical has shown a strong growth trend, achieving a revenue of 2.28 billion yuan in the first three quarters of 2025, a year-on-year increase of 11.48%, and a net profit attributable to shareholders of 510 million yuan, up 21.00% year-on-year [3] - The company has developed a product matrix centered around Wuling Capsules, with a focus on expanding into lower-tier markets and enhancing clinical value recognition through targeted marketing strategies [3] Group 3: Strategic Advantages - The company can leverage its market advantages in centralized procurement and essential drug products to synergize with the multi-trace element injection product group, meeting the growing diversified clinical needs [4] - This acquisition is expected to enhance the company's marketing capabilities and team potential, facilitating rapid market entry and deep penetration of the new products [4]